9.71

1.94% 0.185

After Hours: 9.75 0.04 +0.41%

Zevra Therapeutics Inc (ZVRA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Zevra Therapeutics Inc stock is traded at $9.71, with a volume of 1.71M. It is up +1.94% in the last 24 hours and down -28.18% over the past month. Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Previous Close:

$9.525

Open:

$9.53

24h Volume:

1.71M

Relative Volume:

1.00

Market Cap:

$574.01M

Revenue:

$122.29M

Net Income/Loss:

$122.31M

P/E Ratio:

4.5081

EPS:

2.1539

Net Cash Flow:

$12.00M

1W Performance:

-19.29%

1M Performance:

-28.18%

6M Performance:

+8.73%

1Y Performance:

-13.54%

1-Day Range:

$9.4703

$9.99

1-Week Range:

$9.10

$12.56

52-Week Range:

$7.16

$15.04

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name

Zevra Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (599)

Phone

(888) 958-1253

Address

101 FEDERAL STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

ZVRA's Discussions on Twitter

Compare ZVRA vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZVRA Zevra Therapeutics Inc	9.71	563.07M	122.29M	122.31M	12.00M	2.1539
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Initiated	BTIG Research	Buy
Jul-02-25	Initiated	H.C. Wainwright	Buy
Jan-08-25	Resumed	Cantor Fitzgerald	Overweight
Oct-07-24	Initiated	Guggenheim	Buy
Sep-24-24	Initiated	JMP Securities	Mkt Outperform
Sep-24-24	Reiterated	Maxim Group	Buy
Apr-02-24	Reiterated	Maxim Group	Buy
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy

View All

Zevra Therapeutics Inc Stock (ZVRA) Latest News

Jul 27, 2026

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law - The AI Journal

Jul 27, 2026

ZVRA Maintains Buy Rating by Canaccord Genuity -- Price Target L - GuruFocus

Jul 27, 2026

Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA) - PR Newswire

Jul 27, 2026

Zevra Europe Entry Plans For Neimann-Pick Drug Put On Hold - insights.citeline.com

Jul 27, 2026

Zevra Therapeutics Market Sentiment - Benzinga España

Jul 27, 2026

Guggenheim cuts Zevra stock price target to $24 on EU setback - Investing.com

Jul 27, 2026

H.C. Wainwright reiterates Zevra stock rating on EU setback By Investing.com - Investing.com Canada

Jul 27, 2026

Canaccord cuts Zevra Therapeutics stock price target on Europe sales By Investing.com - Investing.com Australia

Jul 27, 2026

H.C. Wainwright reiterates Zevra stock rating on EU setback - Investing.com

Jul 27, 2026